SG11202012993SA - Variants of cd38 antibody and uses thereof - Google Patents
Variants of cd38 antibody and uses thereofInfo
- Publication number
- SG11202012993SA SG11202012993SA SG11202012993SA SG11202012993SA SG11202012993SA SG 11202012993S A SG11202012993S A SG 11202012993SA SG 11202012993S A SG11202012993S A SG 11202012993SA SG 11202012993S A SG11202012993S A SG 11202012993SA SG 11202012993S A SG11202012993S A SG 11202012993SA
- Authority
- SG
- Singapore
- Prior art keywords
- variants
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862697730P | 2018-07-13 | 2018-07-13 | |
US201962848874P | 2019-05-16 | 2019-05-16 | |
PCT/EP2019/069028 WO2020012036A1 (en) | 2018-07-13 | 2019-07-15 | Variants of cd38 antibody and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012993SA true SG11202012993SA (en) | 2021-02-25 |
Family
ID=67396922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012993SA SG11202012993SA (en) | 2018-07-13 | 2019-07-15 | Variants of cd38 antibody and uses thereof |
Country Status (21)
Country | Link |
---|---|
US (2) | US20200017600A1 (en) |
EP (1) | EP3820900A1 (en) |
JP (1) | JP2021524276A (en) |
KR (1) | KR20210031932A (en) |
CN (1) | CN112513082A (en) |
AU (1) | AU2019300223A1 (en) |
BR (1) | BR112020026432A2 (en) |
CA (1) | CA3106146A1 (en) |
CL (1) | CL2021000066A1 (en) |
CO (1) | CO2021001544A2 (en) |
CR (1) | CR20210081A (en) |
DO (1) | DOP2021000006A (en) |
EC (1) | ECSP21010092A (en) |
IL (1) | IL279937A (en) |
MA (1) | MA53122A (en) |
MX (1) | MX2020013631A (en) |
PE (1) | PE20211858A1 (en) |
PH (1) | PH12021550054A1 (en) |
SG (1) | SG11202012993SA (en) |
TW (1) | TW202019518A (en) |
WO (1) | WO2020012036A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015000167B1 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN |
US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
WO2023044346A2 (en) | 2021-09-14 | 2023-03-23 | Ausper Biopharma Co., Ltd. | Vaccines for coronavirus prevention and treatment |
AU2022350815A1 (en) * | 2021-09-23 | 2024-05-02 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and application thereof |
US20230134748A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
CN114409788B (en) * | 2022-03-04 | 2022-10-04 | 四川大学华西医院 | anti-CD 38 antibodies and uses thereof |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US835A (en) | 1838-07-12 | X i i i x | ||
US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DK0486622T3 (en) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direct radiolabelling of antibodies and other proteins with technetium or rhenium |
KR970029803A (en) | 1995-11-03 | 1997-06-26 | 김광호 | Precharge Circuit of Semiconductor Memory Device |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
DK2180007T4 (en) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
DK1150918T3 (en) | 1999-02-03 | 2004-12-20 | Biosante Pharmaceuticals Inc | Process for the preparation of therapeutic calcium phosphate particles |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
DE10043437A1 (en) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
MXPA03002974A (en) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Cells producing antibody compositions. |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
BR0213761A (en) | 2001-10-25 | 2005-04-12 | Genentech Inc | Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition |
CN101537180B (en) | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | The recombinant production of mixtures of antibodies |
EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
HUE035250T2 (en) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
KR101866623B1 (en) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | Recombinant monovalent antibodies and methods for production thereof |
BRPI0709598A8 (en) | 2006-03-17 | 2019-01-08 | Biogen Idec Inc | stabilized polypeptide compositions |
ES2395969T3 (en) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Genetically modified heterodimeric protein domains |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
TR201910145T4 (en) | 2006-09-26 | 2019-08-21 | Genmab As | Anti-CD38 plus corticosteroids plus a corticosteroid non-chemotherapeutic for treating tumors. |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
PT2235064E (en) | 2008-01-07 | 2016-03-01 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
HUE043084T2 (en) | 2008-12-19 | 2019-08-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
EP2975051B1 (en) | 2009-06-26 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
MX2012006406A (en) | 2009-12-04 | 2012-07-25 | Genentech Inc | Multispecific antibodies, antibody analogs, compositions, and methods. |
TWI426920B (en) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
JP6022444B2 (en) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | Heterodimeric protein and method for producing and purifying it |
SI2580243T1 (en) * | 2010-06-09 | 2020-02-28 | Genmab A/S | Antibodies against human cd38 |
PL2606064T3 (en) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
JP5758004B2 (en) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific antibodies comprising Fv fragments stabilized by disulfides |
CA2807269A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
CN102250246A (en) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | Bispecific antibody to VEGF/PDGFR beta and application thereof |
US10323081B2 (en) * | 2011-07-06 | 2019-06-18 | Genmag A/S | Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains |
UA117901C2 (en) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
WO2013096291A2 (en) | 2011-12-20 | 2013-06-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
PT2838918T (en) | 2012-04-20 | 2019-08-23 | Merus Nv | Methods and means for the production of heterodimeric ig-like molecules |
BR112015000167B1 (en) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN |
AU2013305885B2 (en) | 2012-08-20 | 2017-12-21 | Gliknik Inc. | Molecules with antigen binding and polyvalent Fc gamma receptor binding activity |
AU2013372331A1 (en) | 2013-01-10 | 2015-07-23 | Genmab B.V. | Human IgG1 Fc region variants and uses thereof |
SI2970456T1 (en) | 2013-03-14 | 2022-01-31 | Translate Bio, Inc. | Methods and compositions for delivering mrna coded antibodies |
ES2670529T3 (en) | 2013-03-15 | 2018-05-30 | Translate Bio, Inc. | Synergistic improvement of nucleic acid delivery through mixed formulations |
KR102376451B1 (en) * | 2013-07-31 | 2022-03-23 | 암젠 인크 | Growth differentiation factor 15 (gdf-15) constructs |
CN106255704A (en) | 2014-04-16 | 2016-12-21 | Ucb生物制药私人有限公司 | Polymer Fc albumen |
US10920246B2 (en) * | 2015-05-26 | 2021-02-16 | Ramot At Tel-Aviv University Ltd. | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
BR112017027990A2 (en) | 2015-06-24 | 2018-08-28 | Janssen Biotech, Inc. | immune modulation and treatment of solid tumors with antibodies that specifically bind to cd38 |
MX2018006333A (en) * | 2015-12-01 | 2018-08-01 | Genmab Bv | Anti-dr5 antibodies and methods of use thereof. |
JP7114465B2 (en) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of drugs |
EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
AU2017286980B2 (en) | 2016-06-30 | 2023-10-26 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
CN110088291A (en) | 2016-12-21 | 2019-08-02 | 豪夫迈·罗氏有限公司 | Method for external Glyco-engineered antibodies |
CA3043158A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
-
2019
- 2019-07-15 TW TW108124908A patent/TW202019518A/en unknown
- 2019-07-15 KR KR1020217003848A patent/KR20210031932A/en unknown
- 2019-07-15 WO PCT/EP2019/069028 patent/WO2020012036A1/en unknown
- 2019-07-15 MX MX2020013631A patent/MX2020013631A/en unknown
- 2019-07-15 CA CA3106146A patent/CA3106146A1/en active Pending
- 2019-07-15 PE PE2021000038A patent/PE20211858A1/en unknown
- 2019-07-15 CN CN201980047066.7A patent/CN112513082A/en active Pending
- 2019-07-15 MA MA053122A patent/MA53122A/en unknown
- 2019-07-15 US US16/512,206 patent/US20200017600A1/en active Pending
- 2019-07-15 CR CR20210081A patent/CR20210081A/en unknown
- 2019-07-15 BR BR112020026432-6A patent/BR112020026432A2/en unknown
- 2019-07-15 AU AU2019300223A patent/AU2019300223A1/en active Pending
- 2019-07-15 JP JP2021500814A patent/JP2021524276A/en active Pending
- 2019-07-15 EP EP19742548.1A patent/EP3820900A1/en active Pending
- 2019-07-15 SG SG11202012993SA patent/SG11202012993SA/en unknown
-
2020
- 2020-02-10 US US16/786,563 patent/US20200165352A1/en active Pending
-
2021
- 2021-01-04 IL IL279937A patent/IL279937A/en unknown
- 2021-01-08 CL CL2021000066A patent/CL2021000066A1/en unknown
- 2021-01-08 PH PH12021550054A patent/PH12021550054A1/en unknown
- 2021-01-11 DO DO2021000006A patent/DOP2021000006A/en unknown
- 2021-02-10 CO CONC2021/0001544A patent/CO2021001544A2/en unknown
- 2021-02-11 EC ECSENADI202110092A patent/ECSP21010092A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021000066A1 (en) | 2021-05-28 |
PE20211858A1 (en) | 2021-09-21 |
BR112020026432A2 (en) | 2021-03-23 |
EP3820900A1 (en) | 2021-05-19 |
CN112513082A (en) | 2021-03-16 |
IL279937A (en) | 2021-03-01 |
AU2019300223A1 (en) | 2021-01-07 |
WO2020012036A1 (en) | 2020-01-16 |
US20200017600A1 (en) | 2020-01-16 |
PH12021550054A1 (en) | 2021-09-27 |
ECSP21010092A (en) | 2021-03-31 |
MX2020013631A (en) | 2021-03-25 |
JP2021524276A (en) | 2021-09-13 |
CO2021001544A2 (en) | 2021-03-08 |
CR20210081A (en) | 2021-06-24 |
DOP2021000006A (en) | 2021-03-15 |
CA3106146A1 (en) | 2020-01-16 |
MA53122A (en) | 2021-05-19 |
US20200165352A1 (en) | 2020-05-28 |
TW202019518A (en) | 2020-06-01 |
KR20210031932A (en) | 2021-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
IL279937A (en) | Variants of cd38 antibody and uses thereof | |
LT3618863T (en) | Anti-tigit antibodies and methods of use thereof | |
ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
IL289813A (en) | Anti-tau antibody and use of same | |
IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
IL277212A (en) | Anti-klk5 antibodies and methods of use | |
IL268568A (en) | Trailshort antibody and methods of use | |
IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
SG11202007443XA (en) | Cd38 protein antibody and application thereof | |
IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
IL273538A (en) | Anti-trkb monoclonal antibodies and methods of use | |
GB201800461D0 (en) | Novel combination and use of antibodies | |
GB201800395D0 (en) | Novel combination and use of antibodies |